Video
In this clip, Gordon Vanscoy, PharmD, MBA, CEO of PANTHERx Specialty Pharmacy, explains how orphan drugs are making an impact on patients in the era of precision medicine.
Gordon Vanscoy, PharmD, MBA, CEO of
PANTHERx
Specialty Pharmacy, explains how orphan drugs are making an impact on patients in the era of precision medicine.
Transcript:
You know the next evolution in medicine is that of precision medicine and as you know originally medicine was based upon symptomatology, how we treated patients. Then, we had the evidence-based medicine era, now we have the precision medicine era and many of the precision medicine products are in fact orphan drugs. These products present such a tremendous hope for patients and these entities, some of them, present a cure and it’s all about understanding the human genome and our ability to go in and change the patient from an adverse situation to a beneficial situation, and believe it or not we’re on the cusp of that science and these products are going to be out there to help our patients today and tomorrow.
FDA Grants Orphan Drug Designation to MDL-101 for Congenital Muscular Dystrophy Type 1a